27.87 USD
-0.53 (-1.87%)
27.99 USD
+0.12 (+0.43%)
TVTX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 525 industry peers in the Biotechnology industry. TVTX may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, TVTX is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
- In the past year TVTX has reported negative net income.
- In the past year TVTX has reported a negative cash flow from operations.
- TVTX had negative earnings in each of the past 5 years.
- In the past 5 years TVTX always reported negative operating cash flow.
1.2 Ratios
- Looking at the Return On Assets, with a value of -16.44%, TVTX is in the better half of the industry, outperforming 78.48% of the companies in the same industry.
- TVTX's Return On Equity of -120.36% is in line compared to the rest of the industry. TVTX outperforms 40.95% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -16.44% | ||
| ROE | -120.36% | ||
| ROIC | N/A |
ROA(3y)-36.55%
ROA(5y)-32.15%
ROE(3y)-416.31%
ROE(5y)-277.75%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- TVTX has a better Gross Margin (97.63%) than 97.33% of its industry peers.
- TVTX's Gross Margin has been stable in the last couple of years.
- TVTX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 97.63% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.11%
GM growth 5Y-0.07%
2. Health
2.1 Basic Checks
- TVTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for TVTX has been increased compared to 1 year ago.
- TVTX has more shares outstanding than it did 5 years ago.
- Compared to 1 year ago, TVTX has a worse debt to assets ratio.
2.2 Solvency
- Based on the Altman-Z score of 0.17, we must say that TVTX is in the distress zone and has some risk of bankruptcy.
- Looking at the Altman-Z score, with a value of 0.17, TVTX is in the better half of the industry, outperforming 61.71% of the companies in the same industry.
- A Debt/Equity ratio of 4.23 is on the high side and indicates that TVTX has dependencies on debt financing.
- TVTX has a worse Debt to Equity ratio (4.23) than 80.19% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 4.23 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.17 |
ROIC/WACCN/A
WACC8.27%
2.3 Liquidity
- TVTX has a Current Ratio of 2.75. This indicates that TVTX is financially healthy and has no problem in meeting its short term obligations.
- TVTX has a Current ratio of 2.75. This is in the lower half of the industry: TVTX underperforms 67.24% of its industry peers.
- TVTX has a Quick Ratio of 2.71. This indicates that TVTX is financially healthy and has no problem in meeting its short term obligations.
- With a Quick ratio value of 2.71, TVTX is not doing good in the industry: 66.29% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.75 | ||
| Quick Ratio | 2.71 |
3. Growth
3.1 Past
- TVTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 75.91%, which is quite impressive.
- TVTX shows a strong growth in Revenue. In the last year, the Revenue has grown by 114.22%.
- Measured over the past years, TVTX shows a small growth in Revenue. The Revenue has been growing by 5.87% on average per year.
EPS 1Y (TTM)75.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%140%
Revenue 1Y (TTM)114.22%
Revenue growth 3Y0.82%
Revenue growth 5Y5.87%
Sales Q2Q%162.11%
3.2 Future
- Based on estimates for the next years, TVTX will show a very strong growth in Earnings Per Share. The EPS will grow by 29.30% on average per year.
- The Revenue is expected to grow by 41.46% on average over the next years. This is a very strong growth
EPS Next Y88.69%
EPS Next 2Y46.14%
EPS Next 3Y34.58%
EPS Next 5Y29.3%
Revenue Next Year116.86%
Revenue Next 2Y72.36%
Revenue Next 3Y55.73%
Revenue Next 5Y41.46%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
- TVTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- TVTX is valuated quite expensively with a Price/Forward Earnings ratio of 50.06.
- Based on the Price/Forward Earnings ratio, TVTX is valued cheaper than 90.48% of the companies in the same industry.
- Compared to an average S&P500 Price/Forward Earnings ratio of 24.29, TVTX is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 50.06 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- TVTX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- A more expensive valuation may be justified as TVTX's earnings are expected to grow with 34.58% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y46.14%
EPS Next 3Y34.58%
5. Dividend
5.1 Amount
- No dividends for TVTX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
27.87
-0.53 (-1.87%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)01-12 2026-01-12/amc
Earnings (Next)04-29 2026-04-29
Inst Owners112.9%
Inst Owner Change-0.12%
Ins Owners0.79%
Ins Owner Change-1.91%
Market Cap2.49B
Revenue(TTM)435.83M
Net Income(TTM)-88.54M
Analysts84.76
Price Target43.06 (54.5%)
Short Float %14.74%
Short Ratio6.49
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)143%
Min EPS beat(2)53.91%
Max EPS beat(2)232.09%
EPS beat(4)3
Avg EPS beat(4)68.35%
Min EPS beat(4)-27.29%
Max EPS beat(4)232.09%
EPS beat(8)4
Avg EPS beat(8)26.91%
EPS beat(12)6
Avg EPS beat(12)-40.48%
EPS beat(16)6
Avg EPS beat(16)-36.6%
Revenue beat(2)2
Avg Revenue beat(2)31.6%
Min Revenue beat(2)11.48%
Max Revenue beat(2)51.72%
Revenue beat(4)3
Avg Revenue beat(4)17.32%
Min Revenue beat(4)-0.02%
Max Revenue beat(4)51.72%
Revenue beat(8)6
Avg Revenue beat(8)9.84%
Revenue beat(12)9
Avg Revenue beat(12)2.67%
Revenue beat(16)9
Avg Revenue beat(16)-7.53%
PT rev (1m)1.72%
PT rev (3m)15.78%
EPS NQ rev (1m)-11.32%
EPS NQ rev (3m)52.97%
EPS NY rev (1m)0%
EPS NY rev (3m)58.33%
Revenue NQ rev (1m)-0.56%
Revenue NQ rev (3m)18.91%
Revenue NY rev (1m)-0.16%
Revenue NY rev (3m)19.49%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 50.06 | ||
| P/S | 5.72 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 33.9 | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.06
EYN/A
EPS(NY)0.56
Fwd EY2%
FCF(TTM)-1.2
FCFYN/A
OCF(TTM)-0.66
OCFYN/A
SpS4.87
BVpS0.82
TBVpS-0.4
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -16.44% | ||
| ROE | -120.36% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 97.63% | ||
| FCFM | N/A |
ROA(3y)-36.55%
ROA(5y)-32.15%
ROE(3y)-416.31%
ROE(5y)-277.75%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.11%
GM growth 5Y-0.07%
F-Score6
Asset Turnover0.81
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 4.23 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 89.32% | ||
| Cap/Sales | 11.21% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.75 | ||
| Quick Ratio | 2.71 | ||
| Altman-Z | 0.17 |
F-Score6
WACC8.27%
ROIC/WACCN/A
Cap/Depr(3y)142.8%
Cap/Depr(5y)123.81%
Cap/Sales(3y)28.66%
Cap/Sales(5y)21.8%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)75.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%140%
EPS Next Y88.69%
EPS Next 2Y46.14%
EPS Next 3Y34.58%
EPS Next 5Y29.3%
Revenue 1Y (TTM)114.22%
Revenue growth 3Y0.82%
Revenue growth 5Y5.87%
Sales Q2Q%162.11%
Revenue Next Year116.86%
Revenue Next 2Y72.36%
Revenue Next 3Y55.73%
Revenue Next 5Y41.46%
EBIT growth 1Y67.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year106.01%
EBIT Next 3Y45.04%
EBIT Next 5Y34.35%
FCF growth 1Y64.78%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y77.81%
OCF growth 3YN/A
OCF growth 5YN/A
TRAVERE THERAPEUTICS INC / TVTX FAQ
What is the ChartMill fundamental rating of TRAVERE THERAPEUTICS INC (TVTX) stock?
ChartMill assigns a fundamental rating of 3 / 10 to TVTX.
What is the valuation status for TVTX stock?
ChartMill assigns a valuation rating of 3 / 10 to TRAVERE THERAPEUTICS INC (TVTX). This can be considered as Overvalued.
How profitable is TRAVERE THERAPEUTICS INC (TVTX) stock?
TRAVERE THERAPEUTICS INC (TVTX) has a profitability rating of 2 / 10.